News
Recent News
07/25/2024
Growth of Early-Stage Resident Companies Marks the Third Anniversary of Johnson & Johnson Innovation – JLABS @ Washington, DC
Celebration of the three-year anniversary of JLABS @ Washington, DC (JLABS DC), it’s great timing to highlight recent accomplishments and milestones reached by incubating and regional companies. Additionally, JLABS DC is excited to share new access to specialized lab equipment to support more innovators within the region. Since the start of 2024, there has been …
07/19/2024
Capra Biosciences Lands $7.5 Million Project Agreement To Demonstrate Platform To Rapidly Scale Pharmaceutical Ingredient Manufacturing
Many ingredients that make up the pharmaceuticals Americans rely on are manufactured overseas. When supply chain issues or shortages occur, as witnessed during the COVID pandemic, it can negatively impact millions of Americans and affect national security. The White House issued an Executive Order in 2022 to stimulate U.S. biomanufacturing. Increasing American biomanufacturing, will provide …
07/18/2024
Virginia Companies Expand into Global Markets through Commonwealth’s Trade Accelerator Program
Governor Glenn Youngkin announced that 11 companies across the Commonwealth have graduated from the Virginia Economic Development Partnership’s (VEDP) Virginia Leaders in Export Trade (VALET) program and 14 companies have joined the two-year program. VALET, which now has 402 graduated companies, assists Virginia exporters that have firmly established domestic operations and are committed to international …
“Robert is a proven industry leader with extensive and highly relevant experience in Ophthalmology and DED,” said Anil Asrani, President and CEO of TearSolutions. “I am genuinely excited and honored to have Robert join our board, as we work together to bring next generation therapeutics to patients suffering from the maladies associated with ocular surface disease.”
“I’m thrilled to work closely with the TearSoultions team to help advance their programs and take the Company to the next level,” said Robert Dempsey. “With their lead product’s highly differentiated and well-characterized mechanism of action, human clinical data illustrating speed of relief, safety, and a best-in-class tolerability profile, as well as the potential to work in a majority of patients, I believe we have a novel disease-modifying solution that can bring much needed relief to patients as well as their treating physicians.”
Robert brings more than two decades of domestic and global leadership experience in the Ophthalmology space driving successful drug development in public and private sectors through efficient organizational structure and capital investments. His widespread experience in Ophthalmology stems from diverse leadership roles across commercial, business development, medical affairs, and venture-backed startups. Currently, Robert serves as the Chief Executive Officer at AsclepiX Therapeutics focused on advancing an integrin regulating peptide for posterior segment diseases and recently led a successful Series A-3 financing. He joined Asclepix in 2021, after serving as the Chief Executive Officer for TearClear where he accelerated the business and commercial strategies including a successful Series B financing and positive FDA engagements. Prior to that, he served as the Global Head of Ophthalmology at Shire, then Takeda, responsible for one of the top ten largest biopharma M&A deals in 2019, the divestiture of Xiidra® (lifitegrast ophthalmic solution) 5%, to Novartis in June 2019 for up to $5.3B.